Thanks for posting this abstract mnpedaler. I just wanted to add a few comments. The FUSE study was observational only; no new treatment with Exubera was conducted. These were subjects that were treated with Exubera in the original trials. Additionally, for this observational study there was no exclusion criteria related to cancer.
Importantly, all the subjects in the original trials diagnosed with lung cancer had a history of smoking.
http://clinicaltrials.gov/ct2/show/NCT00734591?term=fuse&rank=2
That data was used and combined with the prospective study (FUSE), if I interpret this abstract correctly. The abstract does not have any correlative data to smoking/non-smoking, which should be key information in understanding the risk of inhaled insulin.
